Beck Mack & Oliver LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 6.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,200 shares of the medical research company’s stock after selling 400 shares during the quarter. Beck Mack & Oliver LLC’s holdings in Amgen were worth $1,068,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Camelot Portfolios LLC acquired a new position in shares of Amgen during the 1st quarter worth $1,429,000. PGGM Investments grew its stake in shares of Amgen by 2.3% during the 2nd quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after purchasing an additional 15,059 shares during the period. Shelton Capital Management grew its stake in shares of Amgen by 82.7% during the 1st quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after purchasing an additional 49,354 shares during the period. Greylin Investment Mangement Inc. grew its stake in shares of Amgen by 466.9% during the 2nd quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock worth $2,416,000 after purchasing an additional 11,555 shares during the period. Finally, Cadence Bank NA grew its stake in shares of Amgen by 6.2% during the 1st quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after purchasing an additional 197 shares during the period. 78.09% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts recently commented on the stock. Cann reiterated a “buy” rating on shares of Amgen in a research report on Monday, August 28th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research report on Thursday, September 7th. Deutsche Bank AG assumed coverage on shares of Amgen in a research report on Friday, June 23rd. They issued a “hold” rating and a $172.00 price objective on the stock. ValuEngine lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, William Blair reiterated a “market perform” rating on shares of Amgen in a research report on Monday, June 26th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Amgen presently has an average rating of “Buy” and a consensus target price of $186.14.
Amgen Inc. (AMGN) opened at 186.32 on Wednesday. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The stock’s 50 day moving average is $175.99 and its 200 day moving average is $169.31. The stock has a market capitalization of $135.95 billion, a price-to-earnings ratio of 16.97 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same period last year, the company posted $2.84 EPS. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts forecast that Amgen Inc. will post $12.57 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.47%. Amgen’s payout ratio is presently 41.93%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.